Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Keratosis, Actinic 11Pain 3Breast Neoplasms 3Pain, Postoperative 2Non-melanoma Skin Cancer 2Lymphoma, Follicular 2Lung Neoplasms 2Acute Pain 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Respiratory Aspiration 1Prostatic Hyperplasia 1Pneumothorax 1Pleural Neoplasms 1Pleural Effusion 1Photosensitivity Disorders 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lower Urinary Tract Symptoms 1Hematuria 1Hand-Foot Syndrome 1Empyema, Pleural 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Diclofenac × Clear all
NCT01596647 2020-12-21

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡